These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 18378269)

  • 1. Quantification of the antimalarial piperaquine in plasma.
    Tarning J; Lindegardh N
    Trans R Soc Trop Med Hyg; 2008 May; 102(5):409-11. PubMed ID: 18378269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism of Piperaquine to Its Antiplasmodial Metabolites and Their Pharmacokinetic Profiles in Healthy Volunteers.
    Liu H; Zhou H; Cai T; Yang A; Zang M; Xing J
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria.
    Tarning J; Rijken MJ; McGready R; Phyo AP; Hanpithakpong W; Day NP; White NJ; Nosten F; Lindegardh N
    Antimicrob Agents Chemother; 2012 Apr; 56(4):1997-2007. PubMed ID: 22252822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simplified antimalarial therapeutic monitoring: using the day-7 drug level?
    White NJ; Stepniewska K; Barnes K; Price RN; Simpson J
    Trends Parasitol; 2008 Apr; 24(4):159-63. PubMed ID: 18353727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants.
    Creek DJ; Bigira V; McCormack S; Arinaitwe E; Wanzira H; Kakuru A; Tappero JW; Sandison TG; Lindegardh N; Nosten F; Aweeka FT; Parikh S
    J Infect Dis; 2013 Jun; 207(11):1646-54. PubMed ID: 23447696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin-Piperaquine for Uncomplicated Malaria.
    Sambol NC; Yan L; Creek DJ; McCormack SA; Arinaitwe E; Bigira V; Wanzira H; Kakuru A; Tappero JW; Lindegardh N; Tarning J; Nosten F; Aweeka FT; Parikh S
    Clin Pharmacol Ther; 2015 Jul; 98(1):87-95. PubMed ID: 25732044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria.
    Moore BR; Benjamin JM; Salman S; Griffin S; Ginny E; Page-Sharp M; Robinson LJ; Siba P; Batty KT; Mueller I; Davis TM
    Antimicrob Agents Chemother; 2014 Oct; 58(10):5784-94. PubMed ID: 25049242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mass campaigns with antimalarial drugs: a modelling comparison of artemether-lumefantrine and DHA-piperaquine with and without primaquine as tools for malaria control and elimination.
    Gerardin J; Eckhoff P; Wenger EA
    BMC Infect Dis; 2015 Mar; 15():144. PubMed ID: 25887935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LC-MS/MS quantitation of antimalarial drug piperaquine and metabolites in human plasma.
    Aziz MY; Hoffmann KJ; Ashton M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Sep; 1063():253-258. PubMed ID: 28863865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic comparison of two piperaquine-containing artemisinin combination therapies in Papua New Guinean children with uncomplicated malaria.
    Salman S; Page-Sharp M; Batty KT; Kose K; Griffin S; Siba PM; Ilett KF; Mueller I; Davis TM
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3288-97. PubMed ID: 22470119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting the parasite killing effect of artemisinin combination therapy in a murine malaria model.
    Patel K; Batty KT; Moore BR; Gibbons PL; Kirkpatrick CM
    J Antimicrob Chemother; 2014 Aug; 69(8):2155-63. PubMed ID: 24777899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A liquid-liquid LC/MS/MS assay for the determination of artemether and DHA in malaria patient samples.
    Wiesner L; Govender K; Meredith SA; Norman J; Smith PJ
    J Pharm Biomed Anal; 2011 May; 55(2):373-8. PubMed ID: 21353430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Piperaquine concentration and malaria treatment outcomes in Ugandan children treated for severe malaria with intravenous Artesunate or quinine plus Dihydroartemisinin-Piperaquine.
    Byakika-Kibwika P; Ssenyonga R; Lamorde M; Blessborn D; Tarning J
    BMC Infect Dis; 2019 Dec; 19(1):1025. PubMed ID: 31795967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of in vitro/in vivo blood distribution and pharmacokinetics of artemisinin, artemether and dihydroartemisinin in rats.
    Dai T; Jiang W; Guo Z; Xie Y; Dai R
    J Pharm Biomed Anal; 2019 Jan; 162():140-148. PubMed ID: 30240987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of imported Plasmodium falciparum malaria: role of the combination of dihydroartemisinin and piperaquine].
    Le Garlantezec P; Richard C; Broto H; Rapp C
    Med Sante Trop; 2015; 25(2):136-40. PubMed ID: 25296031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single LC-tandem mass spectrometry method for the simultaneous determination of 14 antimalarial drugs and their metabolites in human plasma.
    Hodel EM; Zanolari B; Mercier T; Biollaz J; Keiser J; Olliaro P; Genton B; Decosterd LA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Apr; 877(10):867-86. PubMed ID: 19249251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling Prevention of Malaria and Selection of Drug Resistance with Different Dosing Schedules of Dihydroartemisinin-Piperaquine Preventive Therapy during Pregnancy in Uganda.
    Wallender E; Zhang N; Conrad M; Kakuru A; Muhindo M; Tumwebaze P; Kajubi R; Mota D; Legac J; Jagannathan P; Havlir D; Kamya M; Dorsey G; Aweeka F; Rosenthal PJ; Savic RM
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects.
    Röshammar D; Hai TN; Friberg Hietala S; Van Huong N; Ashton M
    Eur J Clin Pharmacol; 2006 May; 62(5):335-41. PubMed ID: 16570188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of human urinary metabolites of the antimalarial piperaquine.
    Tarning J; Bergqvist Y; Day NP; Bergquist J; Arvidsson B; White NJ; Ashton M; Lindegårdh N
    Drug Metab Dispos; 2006 Dec; 34(12):2011-9. PubMed ID: 16956956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variable piperaquine exposure significantly impacts protective efficacy of monthly dihydroartemisinin-piperaquine for the prevention of malaria in Ugandan children.
    Sundell K; Jagannathan P; Huang L; Bigira V; Kapisi J; Kakuru MM; Savic R; Kamya MR; Dorsey G; Aweeka F
    Malar J; 2015 Sep; 14():368. PubMed ID: 26403465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.